Background and Aims: During liver transplantation, hepatocellular carcinoma (HCC) recurrence remains a critical challenge for patient survival. Targeted therapies, such as sorafenib and regorafenib, have been utilized to manage relapsed HCC in this unique setting. This study aimed to assess the efficacy of Sorafenib and Regorafenib in patients with HCC who experienced recurrence after liver transplantation. We focused on survival outcomes, treatment responses, and the management of side effects in this patient group. Methods: We conducted a retrospective analysis of 73 patients who experienced HCC recurrence post-liver transplantation between 2012 and 2022 across 11 oncology centers in Turkey. Patients were categorized according to Child–Pugh classification and treated with sorafenib as first-line therapy and Regorafenib in case of progression. Survival rates were analyzed using the Kaplan–Meier method, and risk factors were evaluated using Cox regression analysis. Results: Of the 73 patients included in the study, 62 were male (84.9%), and 11 were female (15.1%), with a mean age of 61.5 ± 10.9 years. All patients received sorafenib as first-line treatment. Among patients who experienced progression with sorafenib or discontinued treatment due to toxicity, 45.2% (n= 33) continued treatment with regorafenib. The median progression-free survival (PFS1) time with sorafenib was 5.6 months, and the one-year survival rate was 24.3%. The median progression-free survival (PFS2) time with regorafenib, which was administered as second-line treatment, was also calculated as 5.9 months. Overall survival (OS) duration was determined as 35.9 months. The most common side effects associated with both drugs included fatigue, hand and foot syndrome, and hypertension. Significantly better survival outcomes were shown in the Child–Pugh A group compared to other patients. Conclusions: These results suggest that Sorafenib and Regorafenib treatments offer a survival advantage in patients with relapsed HCC post-transplantation. However, individualized treatment strategies and close follow-up are crucial for optimizing outcomes. Further studies are needed to refine therapeutic protocols and enhance the care of this specific patient group.
**背景与目的：** 肝细胞癌（HCC）复发是肝移植术后影响患者生存的关键挑战。在此特殊背景下，索拉非尼和瑞戈非尼等靶向疗法已被用于治疗复发性HCC。本研究旨在评估索拉非尼和瑞戈非尼在肝移植术后HCC复发患者中的疗效，重点关注该患者群体的生存结局、治疗反应及副作用管理。 **方法：** 我们对土耳其11个肿瘤中心在2012年至2022年间收治的73例肝移植术后HCC复发患者进行了回顾性分析。患者根据Child-Pugh分级进行分类，一线治疗采用索拉非尼，若疾病进展则使用瑞戈非尼。采用Kaplan-Meier法分析生存率，并采用Cox回归分析评估风险因素。 **结果：** 纳入研究的73例患者中，男性62例（84.9%），女性11例（15.1%），平均年龄为61.5 ± 10.9岁。所有患者均接受索拉非尼作为一线治疗。在索拉非尼治疗期间出现进展或因毒性停药的患者中，45.2%（n=33）继续接受了瑞戈非尼治疗。索拉非尼治疗的中位无进展生存期（PFS1）为5.6个月，一年生存率为24.3%。作为二线治疗的瑞戈非尼，其中位无进展生存期（PFS2）计算为5.9个月。总生存期（OS）确定为35.9个月。两种药物最常见的不良反应包括疲劳、手足综合征和高血压。与其他患者相比，Child-Pugh A级患者的生存结局显著更优。 **结论：** 这些结果表明，索拉非尼和瑞戈非尼治疗为移植后复发性HCC患者提供了生存获益。然而，个体化治疗策略和密切随访对于优化结局至关重要。需要进一步研究以完善治疗方案，并加强对这一特定患者群体的照护。
肿瘤(癌症)患者之家